Co‐Delivery of aPD‐L1 and CD73 Inhibitor Using Calcium Phosphate Nanoparticles for Enhanced Melanoma Immunotherapy with Reduced Toxicity
Open Access
- 24 December 2024
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 12 (7) , e2410545
Abstract
Melanoma, a malignant skin tumor, presents significant treatment challenges, particularly in unresectable and metastatic cases. While immune checkpoint inhibitors (ICIs) targeting PD‐1/PD‐L1 have brought new hope, their efficacy is limited by low response rates and significant immune‐mediated adverse events (irAEs). Through multi‐omics data analysis, it is discovered that the spatial co‐localization of CD73 and PD‐L1 in melanoma correlates with improved progression‐free survival (PFS), suggesting a synergistic potential of their inhibitors. Building on these insights, a novel therapeutic strategy using calcium phosphate (CaP) nanoparticles is developed for the co‐delivery of aPD‐L1 and APCP, a CD73 inhibitor. These nanoparticles, constructed via a biomineralization method, exhibit high drug‐loading capacity and pH‐responsive drug release. Compared to free aPD‐L1, the CaP‐delivered aPD‐L1 effectively avoids systemic side effects while significantly enhancing anti‐tumor efficacy, surpassing even a 20‐fold dose of free aPD‐L1. Furthermore, the co‐delivery of aPD‐L1 and APCP via CaP nanoparticles demonstrates a synergistic anti‐tumor effect, with substantial immune activation and prevention of tumor recurrence through immune memory effects. These findings suggest that the co‐delivery of aPD‐L1 and APCP using CaP nanoparticles is a promising approach for improving melanoma immunotherapy, achieving enhanced efficacy and reduced toxicity.Keywords
Funding Information
- National Key Research and Development Program of China (2022YFC2504700)
- National Natural Science Foundation of China (8217300)
- China Postdoctoral Science Foundation (2023M733954)
- National Postdoctoral Program for Innovative Talents (BX20230432)
This publication has 44 references indexed in Scilit:
- Advances of calcium phosphate nanoceramics for the osteoinductive potential and mechanistic pathways in maxillofacial bone defect repairNano TransMed, 2024
- Three‐dimensional printed biomimetic multilayer scaffolds coordinated with sleep‐related small extracellular vesicles: A strategy for extracellular matrix homeostasis and macrophage polarization to enhance osteochondral regenerationView, 2024
- Biomineralized nanomedicine for enhanced cancer therapy through in situ toxification and amplified Ca2+ overloadChemical Engineering Journal, 2023
- Recent progress of vaccines administration via microneedles for cancer immunotherapyChinese Chemical Letters, 2023
- Reversing the negative effect of adenosine A1 receptor-targeted immunometabolism modulation on melanoma by a co-delivery nanomedicine for self-activation of anti-PD-L1 DNAzymeNano Today, 2022
- Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced MelanomaJAMA Oncology, 2022
- Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumorsMedcomm, 2021
- Nanomedicine‐Based Immunotherapy for the Treatment of Cancer MetastasisAdvanced Materials, 2019
- Regulation and Function of the PD-L1 CheckpointImmunity, 2018
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016